Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.
Ebola
Ebola vaccine
Ebola virus
Ebola virus disease
STRIVE
Sierra Leone
Sierra Leone Trial to Introduce a Vaccine against Ebola
West Africa
pregnancy
rVSVΔ-ZEBOV-GP
vaccine safety
vaccine-preventable diseases
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
6
2
2020
medline:
16
3
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Little information exists regarding Ebola vaccine rVSVΔG-ZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) randomized participants without blinding to immediate or deferred (18-24 weeks postenrollment) vaccination. Pregnancy was an exclusion criterion, but 84 women were inadvertently vaccinated in early pregnancy or became pregnant <60 days after vaccination or enrollment. Among immediate vaccinated women, 45% (14/31) reported pregnancy loss, compared with 33% (11/33) of unvaccinated women with contemporaneous pregnancies (relative risk 1.35, 95% CI 0.73-2.52). Pregnancy loss was similar among women with higher risk for vaccine viremia (conception before or <14 days after vaccination) (44% [4/9]) and women with lower risk (conception >15 days after vaccination) (45% [10/22]). No congenital anomalies were detected among 44 live-born infants examined. These data highlight the need for Ebola vaccination decisions to balance the possible risk for an adverse pregnancy outcome with the risk for Ebola exposure.
Identifiants
pubmed: 32017677
doi: 10.3201/eid2603.191018
pmc: PMC7045819
doi:
Substances chimiques
Ebola Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02378753']
PACTR
['PACTR201502001037220']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-548Références
Lancet. 2019 Nov 23;394(10212):1893
pubmed: 31777382
Lancet. 1999 Aug 14;354(9178):566
pubmed: 10470704
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
Int J Gynaecol Obstet. 2018 Jul;142(1):71-77
pubmed: 29569244
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
PLoS Negl Trop Dis. 2012;6(3):e1567
pubmed: 22448291
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
J Infect Dis. 1999 Feb;179 Suppl 1:S11-2
pubmed: 9988157
Birth Defects Res. 2017 Mar 15;109(5):353-362
pubmed: 28398679
MMWR Suppl. 2016 Jul 08;65(3):98-106
pubmed: 27387395
Vaccine X. 2019 Jan 29;1:100009
pubmed: 31384731
J Infect Dis. 2017 Jun 15;215(12):1789-1798
pubmed: 28549145
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Clin Infect Dis. 2017 Jul 15;65(2):292-299
pubmed: 28379374
Lancet Infect Dis. 2015 Oct;15(10):1156-1166
pubmed: 26248510
PLoS Med. 2017 Oct 6;14(10):e1002402
pubmed: 28985239
J Clin Microbiol. 1977 Oct;6(4):437-8
pubmed: 199615
Vaccine. 2019 May 3;:
pubmed: 31060949
Lancet. 2011 Mar 5;377(9768):849-62
pubmed: 21084112
CMAJ. 2017 Jun 19;189(24):E819-E827
pubmed: 28630358
Hum Reprod Update. 2016 Jan-Feb;22(1):116-33
pubmed: 26386469
NCHS Data Brief. 2013 Dec;(136):1-8
pubmed: 24314113
Vaccine. 2019 Nov 15;37(48):7171-7177
pubmed: 30266489
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15
pubmed: 29788345
N Engl J Med. 2017 Jan 26;376(4):330-341
pubmed: 25830322
Wkly Epidemiol Rec. ;92(22):301-20
pubmed: 28580777
Obstet Gynecol. 2017 May;129(5):e150-e154
pubmed: 28426621